A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance) Meeting Abstract
| Authors: | Halabi, S.; Luo, B.; Guo, S. S.; Knutson, T.; Lyman, J.; Kobilka, A.; Beltran, H.; Antonarakis, E. S.; Rosenberg, J. E.; Galsky, M. D.; Ryan, C. J.; Kelly, W. K.; Small, E. J.; Morris, M. J.; Dehm, S. M.; Armstrong, A. J. |
| Abstract Title: | A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401254 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.5007 |
| Notes: | Meeting Abstract: 5007 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work